Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis

Inclusion Criteria: 1. age 18-70 years old, gender is not limited; 2. Newly diagnosed pancreatic cancer with liver metastasis confirmed by pathology or consistent with clinical diagnosis, and no metastases to organs other than the liver; 3. Imaging evaluable tumors with safe access to puncture; 4. The number of half liver tumors ≤3 and the size of each tumor ≤3 cm; 5. ECOG PS score ≤2 points, expected survival \> 3 months. Exclusion Criteria: 1. Liver function Child-Pugh grade C, severe jaundice, especially obstructive jaundice; 2. The liver is significantly atrophy, the tumor is too large, and the ablation range needs to reach one-third of the liver volume; 3. Expected survival \< 3 months; 4. serious heart, lung, liver and kidney dysfunction and coagulation dysfunction; 5. Uncontrolled co-morbidities, including poorly controlled hypertension or diabetes, persistent active infections, or mental illness or social conditions that may affect participants' compliance with the study; 6. refractory ascites, pleural fluid or bad fluid; 7. Pregnancy or breastfeeding; 8. The researcher considers that there are any other factors that are not suitable for inclusion or affect the participant's participation in the study.